ABVC BioPharma, Inc.
ABVC
$0.96
-$0.10-9.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -39,900.00% | 104.47% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -39,900.00% | 104.47% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -39,900.00% | 104.63% | -- |
| SG&A Expenses | -66.54% | 131.80% | 221.66% | 196.02% | 141.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -107.69% | -130.99% | -- |
| Total Operating Expenses | -66.03% | 126.91% | 191.90% | 180.84% | 134.85% |
| Operating Income | 66.03% | -126.91% | -298.80% | -276.80% | -166.83% |
| Income Before Tax | 64.90% | -78.98% | -378.64% | -164.22% | -99.36% |
| Income Tax Expenses | -- | -- | -- | 25.00% | 121.28% |
| Earnings from Continuing Operations | 65.26% | -78.98% | -378.64% | -164.16% | -122.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.03% | 27.03% | 283.85% | -55.77% | -27.88% |
| Net Income | 67.35% | -85.27% | -387.00% | -215.73% | -139.52% |
| EBIT | 66.03% | -126.91% | -298.80% | -276.80% | -166.83% |
| EBITDA | 66.22% | -128.38% | -303.62% | -283.73% | -170.23% |
| EPS Basic | 78.20% | -8.88% | -160.11% | -68.55% | -56.01% |
| Normalized Basic EPS | 79.22% | -16.72% | -81.28% | -129.20% | -53.08% |
| EPS Diluted | 78.20% | -8.88% | -151.45% | -68.55% | -56.01% |
| Normalized Diluted EPS | 79.22% | -16.72% | -81.28% | -129.20% | -53.08% |
| Average Basic Shares Outstanding | 49.88% | 70.02% | 87.32% | 87.47% | 53.57% |
| Average Diluted Shares Outstanding | 49.88% | 70.02% | 87.32% | 87.47% | 53.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |